스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

biokanol pharma gmbh - remifentanilo hidrocloruro - excipientes: hidroxido de sodio (e-524) - anestÉsicos generales - anéstesicos opiodes - remifentanilo

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

biokanol pharma gmbh - remifentanilo hidrocloruro - excipientes: hidroxido de sodio (e-524) - anestÉsicos generales - anéstesicos opiodes - remifentanilo

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

biokanol pharma gmbh - remifentanilo hidrocloruro - excipientes: hidroxido de sodio (e-524) - anestÉsicos generales - anéstesicos opiodes - remifentanilo

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

blue bio pharmaceuticals ltd - glucosamina - excipientes: propilenglicol,polisorbato 80 - productos antiinflamatorios y antirreumÁticos no esteroideos - otros agentes antiinflamatorios y antirreumáticos no esteroideos - glucosamina

유럽 연합 - 스페인어 - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - dihidrocloruro de sapropterina - fenilcetonurias - otros tracto alimentario y metabolismo de los productos, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

유럽 연합 - 스페인어 - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - miglustat - enfermedad de gaucher - otros productos del metabolismo y del tracto alimentario - miglustat dipharma está indicado para el tratamiento oral de pacientes adultos con insuficiencia renal leve a moderado de la enfermedad de gaucher de tipo 1. miglustat dipharma sólo puede ser utilizado en el tratamiento de pacientes en quienes la terapia de reemplazo enzimático no es adecuado. miglustat dipharma está indicado para el tratamiento de la progresiva manifestaciones neurológicas en pacientes adultos y pacientes pediátricos con enfermedad de niemann-pick tipo c de la enfermedad.

페루 - 스페인어 - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

vita pharma sociedad anonima cerrada - vita pharma s.a.c. - droguerÍa - clorhidrato de tramadol; paracetamol; - tableta recubierta - por tableta - - tramadol, combinación con

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

pharmacia nostrum, s.a. - sertralina hidrocloruro - comprimido recubierto con pelÍcula - 100 mg - sertralina hidrocloruro 100 mg - sertralina

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

pharmacia nostrum, s.a. - sertralina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg - sertralina hidrocloruro 50 mg - sertralina

유럽 연합 - 스페인어 - EMA (European Medicines Agency)

taw pharma (ireland) limited - clorhidrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.